Browse the evidence

Consuming ultra-processed milkshakes high in fat and sugar does not produce a statistically significant average increase in postingestive striatal dopamine release in healthy adults, refuting the hypothesis that such foods elicit drug-like dopamine responses.

The idea that ultra-processed foods trigger a massive, drug-like dopamine spike in your brain is not supported by this research. While individual responses vary, the average brain does not show a significant dopamine release after eating these foods. This suggests that overconsumption is likely driven more by behavioral factors, hunger, and hedonic preference (how much you like/want the food) rather than a fixed, overpowering biological addiction mechanism.

Adiposity (BMI, body fat percentage) is not significantly correlated with the magnitude of postingestive striatal dopamine response to ultra-processed foods, contradicting the hypothesis that obesity blunts this response.

Your body fat percentage does not determine how much your brain releases dopamine when you eat. This study found no link between being overweight and a 'blunted' dopamine response. This is encouraging: it means your brain's reward system is not permanently damaged by your weight, and you can influence your food preferences and intake through behavioral strategies.

DPP-4 inhibitors (Sitagliptin, Saxagliptin, Alogliptin, Linagliptin) are generally neutral for cardiovascular outcomes, with specific agents (Saxagliptin, Alogliptin) associated with an increased risk of heart failure hospitalization.

If you have Type 2 Diabetes and Heart Failure, avoid Saxagliptin and Alogliptin. DPP-4 inhibitors are generally neutral for heart health; prefer SGLT2 inhibitors or GLP-1 agonists which offer proven cardiovascular benefits.

In Japanese subjects, obesity (higher BMI) reduces the numerical incretin effect more significantly than glucose intolerance (T2D or IGT status).

If you have Type 2 Diabetes or pre-diabetes, focus on weight management to improve your body's natural hormonal response to food. In Japanese populations, losing weight improves the 'incretin effect' (how your gut signals your pancreas to make insulin) more effectively than just managing blood sugar numbers alone.

Gastrointestinally-mediated glucose disposal (GIGD), a measure of integrated glucose handling including glucagon suppression, is significantly reduced in Type 2 Diabetes and correlates with obesity.

Managing Type 2 Diabetes involves more than just stimulating insulin; it requires suppressing glucagon. Weight loss helps restore this balance, improving how your body disposes of glucose after a meal.

In elderly patients with type 2 diabetes, maintaining the Triglyceride-Glucose index combined with a Body Shape Index (TyG-ABSI) within an optimal range (specifically avoiding both extremely low and extremely high values) is associated with the lowest all-cause mortality risk.

If you have Type 2 Diabetes, standard weight metrics like BMI might not fully capture your mortality risk. Research suggests that a combination of insulin resistance markers (Triglyceride-Glucose index) and body shape (ABSI) provides a more accurate prediction of health outcomes. Crucially, this risk follows a 'U-shape': both extremely high and extremely low values of this combined index are associated with higher mortality. Therefore, the goal is not simply to minimize these numbers, but to maintain them within an optimal, balanced range, while closely monitoring kidney function (eGFR) as it mediates this risk.

Hypothalamic gliosis, measured via MRI T2 signal ratios, is positively associated with higher BMI, hypertension, metabolic syndrome, and lower HDL-C, independent of adiposity.

This research suggests that brain inflammation (gliosis) is linked to heart disease risks like high blood pressure and bad cholesterol, even if you aren't overweight. While you can't easily see this on an MRI, it implies that managing metabolic health through diet and exercise might protect your brain's regulatory centers, potentially lowering your cardiovascular risk.

Elevated Remnant Cholesterol Inflammatory Index (RCII) is independently associated with a significantly higher risk of incident cardiovascular disease (CVD), including heart disease and stroke.

If you are over 45, ask your doctor about your Remnant Cholesterol Inflammatory Index (RCII). It combines your cholesterol levels with inflammation markers to better predict heart disease risk than weight or BMI alone. High RCII indicates a need for targeted lifestyle interventions focusing on both lipid management and inflammation reduction.

RCII partially mediates the association between ABSI and incident CVD, with the mediation proportion increasing across higher ABSI quartiles.

Understanding that inflammation and lipid metabolism (RCII) play a role in how abdominal fat (ABSI) affects heart health can guide more targeted treatments. For those with high ABSI, addressing inflammation may provide additional cardiovascular protection beyond just weight management.

High LDL-C and low HDL-C are more prevalent in women, while hypertriglyceridemia is more prevalent in men in the Iranian adult population.

Lipid profiles differ by gender. Women in this population showed higher rates of low HDL and high cholesterol, while men showed higher rates of high triglycerides. Regular lipid screening is important for both genders, with attention to these specific patterns.

Intensive lifestyle intervention (ILI) targeting weight loss in adults with type 2 diabetes does not improve cognitive function and may leave a legacy of relative cognitive deficits in subgroups with baseline obesity or cardiovascular disease history, an effect not mediated by changes in leptin or VEGF levels.

For individuals with Type 2 Diabetes, especially those with obesity or heart disease history, intensive lifestyle interventions aimed at significant weight loss may not improve cognitive function and might be associated with relative cognitive declines compared to less intensive support. This decline was not explained by changes in leptin or VEGF. Patients should focus on overall metabolic health and cardiovascular risk reduction, but should not expect cognitive enhancement from weight loss alone, and should monitor for any subjective cognitive changes.

GLP-1 receptor agonists reduce hospitalizations for heart failure (HHF) by approximately 10-11%, although their effect on heart failure with reduced ejection fraction (HFrEF) is neutral or potentially harmful in small studies.

If you have Type 2 Diabetes and heart failure, GLP-1 RAs can help reduce the risk of being hospitalized for heart failure. However, if you have a specific type of heart failure where the heart muscle is weak (HFrEF), the data is less clear, and you should discuss the risks and benefits with your doctor.

In healthy humans, disuse-induced muscle atrophy is primarily driven by a significant reduction in muscle protein synthesis (MPS), while muscle protein breakdown (MPB) remains largely unchanged.

If you are immobilized or inactive but healthy, your muscle loss is not because your body is actively destroying muscle tissue, but because it has stopped building it. The primary lever to prevent loss is to restore the stimulus for muscle protein synthesis (e.g., through resistance exercise or adequate protein intake) rather than focusing solely on preventing breakdown.

In disease states (e.g., sepsis, cancer, critical illness), muscle atrophy is driven by both elevated muscle protein breakdown (MPB) and reduced muscle protein synthesis (MPS), mediated by inflammatory cytokines.

If you have a disease involving inflammation (like cancer or sepsis), your muscle loss is driven by both increased breakdown and decreased synthesis due to inflammatory signals. Preventing loss requires addressing the underlying disease and inflammation, not just rest or exercise.

Bariatric surgery significantly reduces the overall incidence of cancer, obesity-related cancers, and cancer-associated mortality in patients with morbid obesity compared to conventional treatment.

For individuals with morbid obesity, bariatric surgery is a highly effective intervention for reducing the risk of developing various cancers, particularly obesity-related types like breast, colorectal, and endometrial cancer, as well as reducing cancer mortality. This benefit is attributed to sustained weight loss and metabolic improvements that are difficult to achieve through lifestyle changes alone.

Bariatric surgery significantly reduces the incidence of specific obesity-related cancers, including hepatocellular, colorectal, pancreatic, gallbladder, breast, endometrial, and ovarian cancers.

Bariatric surgery offers significant protection against several specific types of cancer, particularly those linked to obesity and hormones (breast, endometrial, ovarian) and metabolic factors (liver, colorectal, pancreatic, gallbladder).

Lifestyle interventions alone are often insufficient for long-term weight maintenance due to hormonal and metabolic adaptations that drive weight regain, necessitating adjunctive therapies for many patients.

If you regain weight after lifestyle changes, do not blame yourself. Your body's hormones and metabolism are adapting to store energy. This is a common biological response, and it is why medical guidelines recommend considering additional therapies (like medication) if lifestyle changes alone do not sustain your results.

Sulfonylureas are associated with weight gain, hypoglycemia, and declining long-term efficacy, making them unsuitable as first- or second-line treatments.

Avoid sulfonylureas if possible. They cause weight gain and low blood sugar, and their effectiveness fades over time. Use them only if other, safer options are not available or affordable.

Adipose tissue (AT) dysfunction, rather than fat mass alone, is the primary mechanistic link between obesity and adverse health outcomes, explaining why some individuals with obesity remain metabolically healthy while others with normal weight develop obesity-related diseases.

Your health risk from obesity is not just about how much you weigh, but how your fat tissue is functioning. Factors like visceral fat, inflammation, and insulin sensitivity matter more than BMI alone. Focus on metabolic health markers rather than just the scale.

Gut peptides such as GLP-1 and PYY, along with vagal afferent signaling, play a critical role in homeostatic appetite suppression and satiety signaling.

Your gut produces hormones like GLP-1 and PYY when you eat, which signal your brain to stop eating. This is a natural biological process. Understanding this can help explain why certain foods or eating patterns might affect your satiety levels.

Higher intake of unprocessed red meat and total meat is associated with a significantly higher incidence of atherosclerotic cardiovascular disease (ASCVD) in older adults, partly mediated by gut microbiota-derived metabolites TMAO, gamma-butyrobetaine, and crotonobetaine.

If you are over 65, be mindful of your red meat consumption. This study links higher intake of unprocessed red meat and total meat to a higher risk of heart disease and stroke. The risk is partly explained by how gut bacteria process compounds in red meat into substances like TMAO. You don't need to eliminate red meat entirely, but balancing it with fish, poultry, and plant-based proteins may help lower your cardiovascular risk.

Intensive glucose-lowering strategies significantly increase the risk of severe hypoglycemia compared to standard therapy.

If you are on intensive diabetes treatment to lower your blood sugar significantly, be aware that your risk of severe low blood sugar (hypoglycemia) nearly doubles compared to standard treatment. This risk must be weighed against the benefits for your eyes and kidneys. Regular monitoring and awareness of hypoglycemia symptoms are crucial.

Pioglitazone improves NASH histology without worsening fibrosis in patients with T2DM and MAFLD, but its use is limited by side effects including weight gain, fluid retention, and potential bladder cancer risk.

Pioglitazone (45mg daily) can improve liver inflammation (NASH) in people with type 2 diabetes and fatty liver without worsening scarring. However, it can cause weight gain, fluid retention, and may increase the risk of bladder cancer in some people. It is not recommended for everyone and should be used with caution, especially if you have a history of heart failure or bladder cancer.

Obesity accelerates biological cardiovascular ageing by inducing structural and functional cardiac and vascular changes that mimic those of chronological ageing, independent of traditional risk factors.

Your heart ages based on how you treat it, not just your birth year. Obesity forces your heart to work harder and remodels it to look and function like an older, non-obese heart. Losing weight can reverse these changes, effectively turning back the biological clock of your cardiovascular system.